HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 07, July 2018 – Water management- Technologies for biotech and pharmaceutical industries       » Why sunshine improves mood and makes us smarter       » SGD110 million lab to create healthier foods and sustainable biochemicals       » Entries open for the USD170,000 Ryman Prize       » Could the eye be the window to brain degeneration?       » High vitamin D levels linked to lower cholesterol in children      
BIOBOARD - SINGAPORE
A*STAR’s IMB discovers ELABELA protects against cardiovascular malformations in mice
ELABELA plays important roles during pregnancy to ensure the health and viability of mother and child.

Scientists from A*STAR’s Institute of Medical Biology (IMB) have discovered that the ELABELA hormonal peptide has a new role in the development of pre-eclampsia and heart malformations in mice, a mammalian model with genetic and biological characteristics that closely resemble those of humans. Pre-eclampsia (PE) is the most common pregnancy-related disease. It is a gestational hypertensive syndrome affecting up to 8% of all pregnancies worldwide.

Discovered in 2013 by the Reversade lab, ELABELA is reported in the study as a circulating hormone produced during pregnancy in both mice and humans. It was found that the hormone is secreted by the placenta, and regulates maternal cardiovascular homeostasis through the regulation of placental blood vessel development. These findings might extend to human pregnancies, with potential implications in the therapy and management of common pregnancy complications such as a low birth weight.

Many mechanisms work in concert to orchestrate complex maternal-placental-foetal interactions. Dysregulation of these mechanisms often leads to common pregnancy complications such as pre-eclampsia, characterised by proteinuria (protein in urine) and hypertension. Hypertension is intricately involved in mediating this maternal-placental-foetal balance, and when its function is absent or impaired, mice are predisposed to pre-eclampsia. Mice foetuses lacking ELABELA are also predisposed to cardiovascular malformations.

Prof. Bruno Reversade, research director said, “This work provides a new genetic model of gestational hypertension but also a possible therapeutic intervention point since administration of ELABELA during pregnancy can rescue both the mother and her offspring from the effects of pre-eclampsia.”

The discovery, published online in Science on 29 June 2017, was led by researchers from A*STAR’s Institute of Medical Biology (IMB), Institute of Molecular and Cell Biology (IMCB) and Genome Institute of Singapore (GIS).

Source: A*STAR

Click here for the complete issue.

NEWS CRUNCH  
news Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
Click here to receive APBN e-newsletters once a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Cancer - Therapies and strategies for better patient outcomes
July:
Water management- Technologies for biotech and pharmaceutical industries
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy